Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

ITRM - Iterum Therapeutics plc Stock Price, Fair Value and News

$0.83-0.04 (-4.60%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

ITRM Price Action

Last 7 days

21.1%

Last 30 days

-6.5%

Last 90 days

-9.5%

Trailing 12 Months

-32.8%

ITRM RSI Chart

NovDec2025FebMarAprMayJunJulAug020406080100

ITRM Valuation

Market Cap

38.4M

Price/Earnings (Trailing)

-1.6

Price/Sales (Trailing)

844.86

EV/EBITDA

-1.97

Price/Free Cashflow

-2.61

ITRM Price/Sales (Trailing)

2023202420255001K1.5K2K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ITRM Fundamentals

ITRM Revenue

Revenue (TTM)

37.0K

Oct2018AprJulOct2019AprJulOct0200K400K600K800K

ITRM Earnings

Earnings (TTM)

-24.1M

Earnings Growth (Yr)

-30.26%

Earnings Growth (Qtr)

-33.08%

2018202020222024-100M-50M0

ITRM Profitability

EBT Margin

-64313.51%

Return on Equity

619.4%

Return on Assets

-70.78%

Free Cashflow Yield

-38.38%

ITRM Investor Care

Shares Dilution (1Y)

96.67%

Diluted EPS (TTM)

-0.8

ITRM Alerts

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2018AprJulOct2019AprJulOct0100K200K300K400K500K600K700K800K900K
Net sales
YearQ1Q2Q3Q4
2019715.0K530.0K276.0K37.0K
2018598.3K688.5K778.8K869.0K
2017000508.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Iterum Therapeutics plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEiterumtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES14

Iterum Therapeutics plc Frequently Asked Questions

What is the ticker symbol for Iterum Therapeutics plc? What does ITRM stand for in stocks?

ITRM is the stock ticker symbol of Iterum Therapeutics plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Iterum Therapeutics plc (ITRM)?

As of Mon Aug 18 2025, market cap of Iterum Therapeutics plc is 38.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITRM stock?

You can check ITRM's fair value in chart for subscribers.

Is Iterum Therapeutics plc a good stock to buy?

The fair value guage provides a quick view whether ITRM is over valued or under valued. Whether Iterum Therapeutics plc is cheap or expensive depends on the assumptions which impact Iterum Therapeutics plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITRM.

What is Iterum Therapeutics plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Aug 18 2025, ITRM's PE ratio (Price to Earnings) is -1.6 and Price to Sales (PS) ratio is 844.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITRM PE ratio will change depending on the future growth rate expectations of investors.